Inhibikase Therapeutics (IKT) News Today $1.90 -0.10 (-5.00%) Closing price 04:00 PM EasternExtended Trading$2.03 +0.13 (+6.63%) As of 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Inhibikase Therapeutics Advances PAH Treatment with New LeadershipApril 14 at 11:56 PM | tipranks.comInhibikase Therapeutics announces appointment of McIntyre as CFOApril 14 at 8:25 PM | markets.businessinsider.comInhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial OfficerApril 14 at 8:00 AM | globenewswire.comADAR1 Capital Management LLC Takes $16.59 Million Position in Inhibikase Therapeutics, Inc. (NYSE:IKT)ADAR1 Capital Management LLC bought a new position in shares of Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 5,103,005 shares of the company'April 9, 2025 | marketbeat.comHedge funds owners may consider drastic measures as Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) recent US$29m drop adds to long-term lossesApril 4, 2025 | finance.yahoo.comInhibikase Therapeutics (NYSE:IKT) Earns "Neutral" Rating from HC WainwrightHC Wainwright reaffirmed a "neutral" rating on shares of Inhibikase Therapeutics in a report on Friday.March 29, 2025 | marketbeat.comInhibikase Therapeutics (IKT) Receives a Hold from H.C. WainwrightMarch 29, 2025 | markets.businessinsider.comInhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent ActivityMarch 27, 2025 | globenewswire.comInhibikase Therapeutics (NYSE:IKT) Stock Price Up 4.9% - What's Next?Inhibikase Therapeutics (NYSE:IKT) Stock Price Up 4.9% - Here's What HappenedMarch 18, 2025 | marketbeat.comInhibikase appoints Chris Cabell as president, head of R&D, John Adams as CSOFebruary 24, 2025 | markets.businessinsider.comInhibikase Announces Expansion of Senior Leadership TeamFebruary 24, 2025 | globenewswire.comInhibikase Therapeutics: Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's GrowthFebruary 18, 2025 | finanznachrichten.deInhibikase Therapeutics appoints Mark Iwicki as CEOFebruary 18, 2025 | markets.businessinsider.comInhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s GrowthFebruary 18, 2025 | finance.yahoo.comInhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's GrowthFebruary 18, 2025 | globenewswire.comWhat is HC Wainwright's Estimate for IKT Q1 Earnings?Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) - HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Inhibikase Therapeutics in a research report issued to clients and investors on Wednesday, February 12th. HC Wainwright analyst E. White expects that the company willFebruary 17, 2025 | marketbeat.comHC Wainwright & Co. Downgrades Inhibikase Therapeutics (IKT)February 13, 2025 | msn.comInhibikase Therapeutics downgraded to Neutral from Buy at H.C. WainwrightFebruary 12, 2025 | markets.businessinsider.comInhibikase Therapeutics (NYSE:IKT) Downgraded to Neutral Rating by HC WainwrightHC Wainwright lowered Inhibikase Therapeutics from a "buy" rating to a "neutral" rating in a report on Wednesday.February 12, 2025 | marketbeat.comInhibikase Halts Parkinson's Drug Development to Focus on PAHJanuary 30, 2025 | msn.comInhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in studyJanuary 29, 2025 | reuters.comInhibikase Therapeutics (NYSE:IKT) Shares Down 2.5% - Should You Sell?Inhibikase Therapeutics (NYSE:IKT) Shares Down 2.5% - Here's WhyJanuary 28, 2025 | marketbeat.comBullish Inhibikase Therapeutics Insiders Loaded Up On US$2.70m Of StockJanuary 21, 2025 | finance.yahoo.comInhibikase Therapeutics (NYSE:IKT) Trading 3.4% Higher - Still a Buy?Inhibikase Therapeutics (NYSE:IKT) Shares Up 3.4% - Time to Buy?December 27, 2024 | marketbeat.comInhibikase Therapeutics (NYSE:IKT) Stock Price Up 7% - What's Next?Inhibikase Therapeutics (NYSE:IKT) Trading 7% Higher - Time to Buy?November 30, 2024 | marketbeat.comInhibikase Therapeutics files to sell 58.31M shares of common stock for holdersNovember 19, 2024 | markets.businessinsider.comInhibikase: Potential To Improve Current Treatment Options For PAH PatientsNovember 19, 2024 | seekingalpha.comInhibikase Therapeutics’ Promising Developments and Financial Backing Justify Buy RatingNovember 15, 2024 | markets.businessinsider.comInhibikase Therapeutics: Strategic Developments and Financial Position Underpin Buy RatingNovember 15, 2024 | markets.businessinsider.comInhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent ActivityNovember 14, 2024 | globenewswire.comJefferies Initiates Coverage of Inhibikase Therapeutics (IKT) with Buy RecommendationNovember 9, 2024 | msn.comInhibikase Therapeutics initiated with a Buy at JefferiesNovember 8, 2024 | markets.businessinsider.comInhibikase Therapeutics initiated with a Buy at JefferiesNovember 8, 2024 | markets.businessinsider.comInhibikase Therapeutics: Promising PAH Market Potential and Strategic Advancements Justify Buy RatingNovember 8, 2024 | markets.businessinsider.comInhibikase Therapeutics: Promising PAH Market Potential and Strategic Advancements Justify Buy RatingNovember 8, 2024 | markets.businessinsider.comInhibikase Therapeutics: Strategic Financial Moves and Promising Pipeline Fuel Buy RatingOctober 24, 2024 | markets.businessinsider.comInhibikase Therapeutics, Inc. (NYSE:IKT) Director Arvind Kush Acquires 145,000 SharesOctober 24, 2024 | insidertrades.comPerceptive Advisors LLC Acquires New Stake in Inhibikase Therapeutics IncOctober 22, 2024 | finance.yahoo.comInhibikase Therapeutics Secures Funding and Strengthens LeadershipOctober 22, 2024 | markets.businessinsider.comInhibikase Therapeutics closes up to $275M financing, advances IkT-001ProOctober 22, 2024 | markets.businessinsider.comInhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial HypertensionOctober 21, 2024 | globenewswire.comInhibikase Therapeutics Secures $110M for Drug DevelopmentOctober 12, 2024 | finance.yahoo.comSteven Cohen's Strategic Acquisition of Inhibikase Therapeutics SharesOctober 12, 2024 | finance.yahoo.comInhibikase Therapeutics Unveils PAH and Parkinson’s Drug PipelineOctober 10, 2024 | finance.yahoo.comWhy Inhibikase Therapeutics (IKT) Stock Is Up 50% TodayOctober 10, 2024 | benzinga.comInhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial HypertensionOctober 9, 2024 | globenewswire.comInhibikase Therapeutics, Inc. (NASDAQ:IKT) Q2 2024 Earnings Call TranscriptAugust 16, 2024 | msn.comIKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q2 2024August 15, 2024 | markets.businessinsider.comInhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period ActivityAugust 14, 2024 | globenewswire.comWhat Wall Street expects from Inhibikase Therapeutics's earningsAugust 14, 2024 | markets.businessinsider.com Remove Ads Get Inhibikase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter. Email Address IKT Media Mentions By Week IKT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IKT News Sentiment▼0.330.78▲Average Medical News Sentiment IKT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IKT Articles This Week▼41▲IKT Articles Average Week Remove Ads Get Inhibikase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ORGO News GHRS News ALMS News QURE News BCYC News KURA News URGN News MGTX News IMTX News ARVN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:IKT) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IKT Stock Free IKT Stock Alerts